Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO Preview on TORCH Trial: Treatment Order Matters
Please Note: While this is Still Excellent Background Info, New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

Despite the fact that many of the most anticipated ASCO abstracts are still being withheld until the meeting itself, there is certainly a lot of information in the released abstracts that provide a tantalizing preview and already hint at some important new conclusions. I'll try to provide some ongoing thoughts leading into the meeting coming up in two weeks. The first I want to highlight is the TORCH trial, an international study being presented by Italian lung cancer leader Cesar Gridelli. This study looks at the question of whether the order of therapy matters: patients in this phase III study were randomized to cisplatin/gemcitabine as first line therapy, followed by the EGFR inhibitor Tarceva (erlotinib) on progression, or the reverse of first line Tarceva followed by cisplatin/gemcitabine at progression. A total of 760 patients, not selected for particular histology (55.5% hadadenocarcinomas), smoking status (20.6% never-smokers), race (3.2% East Asian), or EGFR mutation status (not tested), were enrolled. This is in a population that we must presume is likely to have only a small minority of patients as EGFR mutation positive. The results demonstrate that the order of therapy matter and that there are consequences of giving the less optimal treatment first. Specifically, at the time of a planned interim analysis of the ongoing results, the differences in survival were striking enough, 40% worse for those who started with Tarceva, that the trial was closed for further enrollment. The difference in median overall survival is 10.8 months vs. 7.7 months, favoring initial chemotherapy: a statistically and clinically significant difference, to be sure.

The results of the IPASS study illustrate convincingly that patients who don't have an EGFR mutation are better served by receiving initial chemotherapy than an EGFR inhibitor, at least in terms of the striking difference in progression-free survival, though the difference in (preliminary) overall survival wasn't statistically significant at times the IPASS results have been presented thus far. Frankly, my presumption has been that if patients cross over to the best therapy for them, regardless of whether it's first or second line therapy,they'd end up with a very comparable overall survival. We don't know yet whether most of the people enrolled successfully crossed over to the second line treatment option. Perhaps the inferior survival with first line Tarceva was related to many patients not getting the opportunity to benefit from chemo -- and perhaps there wouldn't be any real differences if a more tolerable carboplatin-based doublet were used (I can imagine that patients progressing and having a worse performance status would have more success with a second line carboplatin combination than with cisplatin/gemcitabine). It should also be underscored that these results don't negate the very consistent results thus far that have shown that patients with a known EGFR mutation do exceptionally well with first line oral EGFR inhibitor therapy. The TORCH trial included a very different population. We've certainly got much more to learn than is contained in this abstract, and much will be revealed in the actual oral presentation in a couple of weeks. But based on the synopsis available now, I need to revise my general presumption that "it'll all come out in the wash", as my grandfather used to say. It may not be feasible to have everything come out the same whether you start with option 1 or option 2. Instead, these results from the TORCH trial raise the ante for ensuring that patients get the optimal treatment strategy for them at the earliest opportunity. It directly counters the concept that it's just as good to start with an EGFR inhibitor based on clinical features or a desire to avoid chemotherapy-related side effects. That appears to be an ill-conceived idea unless you know a person has an EGFR mutation.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on